Enlivex ENLV

Enlivex Ltd. is a quality longevity company focused on advancing therapies to extend health span and improve quality of life. The company operates through a dual strategy combining clinical development of immunomodulatory treatments for conditions associated with aging with a digital asset treasury strategy utilizing the RAIN prediction markets protocol. Its lead candidate Allocetra™ is a macrophage reprogramming therapy designed to restore immune balance and address inflammatory and degenerative conditions linked to aging processes.

Enlivex Ltd. generates revenue through yield generating activities on its digital asset treasury which as of December 31 2025 had a fair value of $606.781 million in RAIN tokens. The company employs strategies such as staking, restaking, liquid staking, and participation in decentralized finance protocols on the Arbitrum network to earn staking yields, trading fees, and protocol incentives. These activities are managed under its Treasury Reserve Policy with an emphasis on long term exposure to benefit from RAIN's deflationary buyback and burn mechanism where 2.5% of platform trading volume is allocated to reduce token supply over time.

Enlivex Ltd. operates in the highly competitive biotechnology and pharmaceutical industries where companies pursue various approaches to treat osteoarthritis. While many focus on symptom management or surgical interventions, Enlivex Ltd. distinguishes itself through its novel macrophage reprogramming therapy Allocetra™ which aims to reset immune homeostasis rather than target specific pathways. The company believes this approach offers potential advantages over existing therapies though it faces competition from established players and emerging innovators in the osteoarthritis treatment space. Clinical progress includes positive Phase I/II trial data showing efficacy signals in older patient cohorts supporting its belief in potential differentiation.

Enlivex Ltd. serves patients suffering from osteoarthritis and related inflammatory conditions with current clinical evidence concentrated on knee osteoarthritis in elderly demographics. The company highlights that osteoarthritis impacts more than 32.5 million adults in the United States representing a substantial unmet medical need particularly for treatments that are not invasive and that modify the disease course. Its clinical trials enroll patients with moderate to severe severity who have often failed standard therapies such as pain relievers or lifestyle interventions focusing on the 60 plus age group where preliminary data showed strong correlation between age and treatment response. Beyond direct patient care the company anticipates future engagement with healthcare systems insurance providers and medical institutions responsible for patient care and reimbursement though immediate interactions occur through clinical trial sites aimed at validating Allocetra™s safety and effectiveness.